Anzeige
Mehr »
Samstag, 31.01.2026 - Börsentäglich über 12.000 News
Über 2 Mio. Unzen Gold - und trotzdem erst 59 Mio. USD Börsenwert?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1JLYP | ISIN: KYG211081248 | Ticker-Symbol: 2M7C
Stuttgart
30.01.26 | 21:55
1,490 Euro
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
ASIEN
1-Jahres-Chart
CHINA MEDICAL SYSTEM HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
CHINA MEDICAL SYSTEM HOLDINGS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
1,4601,52030.01.
1,4901,54030.01.

Aktuelle News zur CHINA MEDICAL SYSTEM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrChina Medical System Holdings Ltd.: CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China97SHENZHEN, CHINA, Jan. 30, 2026 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that its subsidiary, Dermavon Holdings Limited ("Dermavon", an...
► Artikel lesen
FrCMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT APPROVAL OF DRUG CLINICAL TRIALS FOR PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INDICATION OF INNOVATIVE ...2
FrCMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT NEW DRUG APPLICATION OF RUXOLITINIB PHOSPHATE CREAM APPROVED IN CHINA THE FIRST AND ONLY TARGETED ...1
22.01.CMS removes OSA coverage for Inspire Medical Systems reimbursement uplift2
15.12.25China Medical System Holdings Ltd.: CMS (867.HK/8A8.SG): Innovative Drug Oral JAK1 Inhibitor Povorcitinib Has Been Included in the List of Breakthrough Therapeutic Drugs in China2
CHINA MEDICAL SYSTEM Aktie jetzt für 0€ handeln
15.12.25CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT INNOVATIVE DRUG ORAL SMALL-MOLECULE JAK1 INHIBITOR POVORCITINIB INCLUDED IN THE LIST OF BREAKTHROUGH ...1
11.12.25China Medical System Holdings Ltd.: CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China2
11.12.25CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT NEW DRUG APPLICATION OF CLASS 1 INNOVATIVE DRUG Y-3 FOR INJECTION FOR ACUTE ISCHEMIC STROKE ACCEPTED ...1
31.10.25CHINA MEDICAL SYSTEM HOLDINGS LIMITED: GENERAL ANNOUNCEMENT::MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2025-
30.10.25China Medical System Holdings Ltd.: CMS (867.HK; 8A8.SG) NDA for AD Indication of Long-acting Anti-IL-4Ra Humanized Monoclonal Antibody Injection MG-K10 Accepted in China1
30.10.25CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT NEW DRUG APPLICATION FOR ATOPIC DERMATITIS INDICATION OF LONG-ACTING ANTI-IL-4RA HUMANIZED MONOCLONAL ...-
27.10.25China Medical System Holdings Ltd.: CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis and Beovu1
27.10.25CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT SIGNING A DISTRIBUTION AGREEMENT FOR OPHTHALMIC DRUGS LUCENTIS AND BEOVU-
30.09.25CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT APPROVAL OF DRUG CLINICAL TRIALS FOR ADDITIONAL CHRONIC OBSTRUCTIVE PULMONARY DISEASE INDICATION ...-
28.09.25China Medical System Holdings Ltd. (867.HK; 8A8.SG) Positive Results from China Phase 3 Clinical Trial of Innovative Drug Ruxolitinib Cream with AD Indication767SHENZHEN, CHINA, Sept. 28, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited ("CMS") is pleased to announce that its subsidiaries, Dermavon Holdings Limited ("Dermavon", an innovative...
► Artikel lesen
26.09.25CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT POSITIVE RESULTS FROM PHASE 3 CLINICAL TRIAL OF RUXOLITINIB CREAM IN CHINESE PATIENTS WITH ATOPIC ...3
26.09.25CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT APPROVAL OF DRUG CLINICAL TRIALS FOR UTERINE FIBROIDS INDICATION OF INNOVATIVE DRUG GNRH RECEPTOR ...-
23.09.25China Medical System Holdings Ltd. (867.HK; 8A8.SG) Signed Collaboration Agreements for Two Innovative Biologics Used for Passive Immunization Against Tetanus and Rabies415SHENZHEN, CHINA, Sept. 23, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 22 September 2025, the Group through its subsidiaries...
► Artikel lesen
22.09.25CMS (00867): VOLUNTARY AND BUSINESS UPDATE ANNOUNCEMENT SIGNING COLLABORATION AGREEMENTS FOR CLASS 1 INNOVATIVE BIOLOGIC RECOMBINANT HUMANIZED ANTI-TETANUS ...1
02.09.25CMS (00867): LETTER TO NON-REGISTERED SHAREHOLDERS - REMINDER LETTER REGARDING THE ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS ...-
Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1